CCS Publications  2024-2025

1.    A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and  validation study in three international cohorts. Lancet Digit Health. 2024;6(7):e507-e519. doi:10.1016/S2589-7500(24)00065-7
2.    Zhao X, Yang M, Fan J, et al. Identification of genetically predicted DNA methylation markers associated with non-small cell lung cancer risk among 34,964 cases and 448,579 controls. Cancer. 2024;130(6):913-926. doi:10.1002/cncr.35130
3.    Wimmer K, Hlauschek D, Balic M, et al. Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials. Breast. 2025;80:104415. doi:10.1016/j.breast.2025.104415
4.    Wimmer K, Hlauschek D, Balic M, et al. Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting? Breast Cancer Res Treat. 2024;206(2):441. doi:10.1007/s10549-024-07351-5
5.    Wimmer K, Hlauschek D, Balic M, et al. Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting? Breast Cancer Res Treat. 2024;205(2):227-239. doi:10.1007/s10549-023-07186-6
6.    Westin JR, Phillips TJ, Mehta A, et al. Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a Phase II study. Blood Adv. Published online February 5, 2025:bloodadvances.2024014907. doi:10.1182/bloodadvances.2024014907
7.    Wessler S, Meisner-Kober N. On the road: extracellular vesicles in intercellular communication. Cell Commun Signal. 2025;23(1):95. doi:10.1186/s12964-024-01999-8
8.    Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. doi:10.1002/jev2.12404
9.    Welponer T, Weber DD, Trattner L, et al. Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive  cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2024;38(1):112-123. doi:10.1111/jdv.19488
10.    Weigl MP, Attenberger C, Feurstein B, et al. Enhanced recovery and reduced conversion rates in robotic rectal cancer surgery: a single-center retrospective cohort study. Langenbecks Arch Surg. 2024;409(1):264. doi:10.1007/s00423-024-03453-2
11.    Wang X, Zhang Z, Ding Y, et al. Impact of individual level uncertainty of lung cancer polygenic risk score (PRS) on risk stratification. Genome Med. 2024;16(1):22. doi:10.1186/s13073-024-01298-4
12.    von Jan J, Timonen S, Braun T, et al. Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses. Blood. 2024;144(15):1595-1610. doi:10.1182/blood.2023022884
13.    Valsalakumari R, Pandya AD, Prasmickaite L, et al. Preclinical Efficacy of Cabazitaxel Loaded Poly(2-alkyl cyanoacrylate) Nanoparticle Variants. Int J Nanomedicine. 2024;19:3009-3029. doi:10.2147/IJN.S450283
14.    Terzić V, Miantezila Basilua J, Billard N, et al. Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial. Clin Infect Dis. 2024;79(2):382-391. doi:10.1093/cid/ciae170
15.    Suske T, Sorger H, Manhart G, et al. Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia. J Clin Invest. 2024;134(8). doi:10.1172/JCI168536
16.    Sumaria N, Fiala GJ, Inácio D, et al. Perinatal thymic-derived CD8αβ-expressing γδ T cells are innate IFN-γ producers that expand in IL-7R-STAT5B-driven neoplasms. Nat Immunol. 2024;25(7):1207-1217. doi:10.1038/s41590-024-01855-4
17.    Sokolova V, Gruber R, Pammer LM, et al. Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target? Mol Biol Rep. 2024;52(1):87. doi:10.1007/s11033-024-10169-5
18.    Singer CF, Jahn SW, Hlauschek D, et al. HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd. Cancer Commun (Lond). Published online January 6, 2025. doi:10.1002/cac2.12657
19.    Siempos II, Kalil AC, Belhadi D, et al. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials. EClinicalMedicine. 2024;69:102472. doi:10.1016/j.eclinm.2024.102472
20.    Sieberer H, Luciano M, Amend D, et al. Inhibition of NLRP3 enhances pro-apoptotic effects of FLT3 inhibition in AML. Cell Commun Signal. 2025;23(1):53. doi:10.1186/s12964-025-02046-w
21.    Shumilov E, Wurm-Kuczera R, Kerkhoff A, et al. Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study. Blood Adv. Published online December 11, 2024:bloodadvances.2024014903. doi:10.1182/bloodadvances.2024014903
22.    Shadman M, Munir T, Robak T, et al. Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up  of SEQUOIA. J Clin Oncol. 2025;43(7):780-787. doi:10.1200/JCO-24-02265
23.    Sassmann R, Gampenrieder SP, Rieder F, et al. Electrotherapy as treatment for chemotherapy-induced peripheral neuropathy - a randomized controlled trial. Front Neurol. 2024;15:1451456. doi:10.3389/fneur.2024.1451456
24.    Rinnerthaler G, Egle D, Bartsch R, et al. Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2  ABCSG-52/ATHENE trial. Nat Cancer. 2025;6(1):41-50. doi:10.1038/s43018-024-00890-2
25.    Ribeiro ARS, Neuper T, Horejs-Hoeck J. The Role of STING-Mediated Activation of Dendritic Cells in Cancer Immunotherapy. Int J Nanomedicine. 2024;19:10685-10697. doi:10.2147/IJN.S477320
26.    Redmer T, Raigel M, Sternberg C, et al. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression. Mol Cancer. 2024;23(1):114. doi:10.1186/s12943-024-02022-x
27.    Rebnegger P, Gantschnigg A, Grechenig M, Emmanuel K, Holzinger J, Singhartinger F. Endoscopic suture-based closure of an enterocutaneous fistula after one-anastomosis gastric bypass. Endoscopy. 2025;57(S 01):E15-E16. doi:10.1055/a-2503-5984
28.    Primavesi F, Senoner T, Schindler S, et al. The Interplay between Perioperative Oxidative Stress and Hepatic Dysfunction after Human Liver Resection: A Prospective Observational Pilot Study. Antioxidants (Basel). 2024;13(5). doi:10.3390/antiox13050590
29.    Presl J, Ehgartner M, Schabl L, et al. Robotic surgery versus conventional laparoscopy in sigmoid colectomy for diverticular disease-a comparison of operative trauma and cost-effectiveness:  retrospective, single-center analysis. Langenbecks Arch Surg. 2024;409(1):200. doi:10.1007/s00423-024-03382-0
30.    Poupardin R, Wolf M, Maeding N, et al. Advances in Extracellular Vesicle Research Over the Past Decade: Source and Isolation Method are Connected with Cargo and Function. Adv Healthc Mater. 2024;13(19):e2303941. doi:10.1002/adhm.202303941
31.    Pölöske D, Sorger H, Schönbichler A, et al. Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma. Hemasphere. 2024;8(12):e70001. doi:10.1002/hem3.70001
32.    Piringer G, Ponholzer F, Thaler J, et al. Prediction of survival after neoadjuvant therapy in locally advanced rectal cancer - a retrospective analysis. Front Oncol. 2024;14:1374592. doi:10.3389/fonc.2024.1374592
33.    Piñón Hofbauer J, Guttmann-Gruber C, Wally V, Sharma A, Gratz IK, Koller U. Challenges and progress related to gene editing in rare skin diseases. Adv Drug Deliv Rev. 2024;208:115294. doi:10.1016/j.addr.2024.115294
34.    Parigger T, Gassner FJ, Drothler S, et al. Combined DNA Analysis from Stool and Blood Samples Improves Tumor Tracking and Assessment of Clonal Heterogeneity in Localized Rectal Cancer Patients. Technol Cancer Res Treat. 2024;23:15330338241252706. doi:10.1177/15330338241252706
35.    Parigger T, Drothler S, Scherhäufl C, et al. Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the  Literature. Acta Haematol. 2024;147(5):604-611. doi:10.1159/000537791
36.    Onida F, Gagelmann N, Chalandon Y, et al. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee. Blood. 2024;143(22):2227-2244. doi:10.1182/blood.2023023476
37.    Noorizadeh R, Sax B, Javaheri T, et al. YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1-mediated reprogramming of bone mesenchymal stem cells. Cell Rep. 2025;44(3):115381. doi:10.1016/j.celrep.2025.115381
38.    Niedersuess-Beke D, Mayrhofer K, Krauter J, et al. Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study. Clin Genitourin Cancer. 2025;23(1):102278. doi:10.1016/j.clgc.2024.102278
39.    Neuper T, Frauenlob T, Dang HH, et al. ADP-heptose attenuates Helicobacter pylori-induced dendritic cell activation. Gut Microbes. 2024;16(1):2402543. doi:10.1080/19490976.2024.2402543
40.    Matikas A, Papakonstantinou A, Loibl S, et al. Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial. Lancet Reg Health Eur. 2025;49:101162. doi:10.1016/j.lanepe.2024.101162
41.    Matikas A, Möbus V, Greil R, et al. Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial. J Clin Oncol. 2024;42(26):3077-3082. doi:10.1200/JCO.24.00178
42.    Machiels JP, Tao Y, Licitra L, et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of  the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2024;25(5):572-587. doi:10.1016/S1470-2045(24)00100-1
43.    Ludwig H, Melchardt T, Sormann S, et al. Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with  newly diagnosed multiple myeloma. Am J Hematol. 2024;99(5):1008-1011. doi:10.1002/ajh.27280
44.    Ludwig H, Melchardt T, Schweitzer I, et al. QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma:  Longitudinal and cross-sectional analysis of the randomized AGMT 02 study. EJHaem. 2024;5(3):494-504. doi:10.1002/jha2.925
45.    Luciano M, Sieberer H, Krenn PW, et al. Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis. Cell Commun Signal. 2024;22(1):424. doi:10.1186/s12964-024-01777-6
46.    Li Y, Xiao X, Li J, et al. Lung Cancer in Ever- and Never-Smokers: Findings from Multi-Population GWAS Studies. Cancer Epidemiol Biomarkers Prev. 2024;33(3):389-399. doi:10.1158/1055-9965.EPI-23-0613
47.    Lessel I, Baresic A, Chinn IK, et al. DNA-binding affinity and specificity determine the phenotypic diversity in BCL11B-related disorders. Am J Hum Genet. 2025;112(2):394-413. doi:10.1016/j.ajhg.2024.12.012
48.    Lahnsteiner A, Ellmer V, Oberlercher A, et al. G-quadruplex forming regions in GCK and TM6SF2 are targets for differential DNA methylation in metabolic disease and hepatocellular carcinoma patients. Sci Rep. 2024;14(1):20215. doi:10.1038/s41598-024-70749-0
49.    Lahnsteiner A, Craig SJC, Kamali K, et al. In vivo detection of DNA secondary structures using permanganate/S1 footprinting with direct adapter ligation and sequencing (PDAL-Seq). Methods Enzymol. 2024;695:159-191. doi:10.1016/bs.mie.2023.12.003
50.    Lafarge MW, Domingo E, Sirinukunwattana K, et al. Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy. NPJ Precis Oncol. 2024;8(1):89. doi:10.1038/s41698-024-00580-3
51.    Krendl FJ, Primavesi F, Oberhuber R, et al. The importance of preclinical models for cholangiocarcinoma drug discovery. Expert Opin Drug Discov. 2025;20(2):205-216. doi:10.1080/17460441.2025.2457637
52.    Koch OO, Leberbauer K, Hitzl W, Wallner E, Emmanuel K. [Ergonomic Load on the Surgical Team during Open, Laparoscopic and Robot-assisted Surgical Procedures]. Zentralbl Chir. Published online January 24, 2025. doi:10.1055/a-2510-8669
53.    Klocker EV, Hasenleithner S, Bartsch R, et al. Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease  progression. Mol Oncol. Published online June 12, 2024. doi:10.1002/1878-0261.13671
54.    Kiesslich T, Mayr C, Bekric D, Neureiter D. New insights into possible HDAC inhibitor resistance in DLBCL - Comment on “defining cellular responses to HDAC-selective inhibitors reveals that efficient  targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve  resistance to pan-HDACi in diffuse large B cell lymphoma” by Havas et al. Transl Oncol. 2024;44:101820. doi:10.1016/j.tranon.2023.101820
55.    Kiem D, Ocker M, Greil R, Neureiter D, Melchardt T. Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical  trials. Expert Opin Investig Drugs. 2024;33(3):229-242. doi:10.1080/13543784.2024.2319317
56.    Karjalainen A, Witalisz-Siepracka A, Prchal-Murphy M, et al. Cell-type-specific requirement for TYK2 in murine immune cells under steady state and challenged conditions. Cell Mol Life Sci. 2025;82(1):98. doi:10.1007/s00018-025-05625-9
57.    Jung T, Neureiter D, Schweighofer-Zwink G, Rendl G, Pirich C, Beheshti M. B-CLL with negative (18)F-FDG PET/CT and intensive solitary lesion on PSMA PET/CT mimicking prostate cancer bone metastases. EJNMMI Rep. 2025;9(1):2. doi:10.1186/s41824-024-00235-3
58.    Jung EM, Pleyer L, Dropco I, et al. Dynamic Contrast Ultrasound Diagnostics (CEUS) of Liver Lesions and Post-treatment Control with A New High-resolution Examination Technique (HiFR)  and Perfusion. J Gastrointestin Liver Dis. 2024;33(3):362-371. doi:10.15403/jgld-5589
59.    Jäger T, Zitt M, Riss S, et al. Does Total Neoadjuvant Therapy Impact Surgical Precision in Total Mesorectal Excision? A Nationwide Survey of the Experiences of Expert Surgeons. Cancers (Basel). 2025;17(2). doi:10.3390/cancers17020283
60.    Huemer F, Weiss L, Regitnig P, et al. Comment on: Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal  junction adenocarcinoma. ESMO Open. 2024;9(4):102973. doi:10.1016/j.esmoop.2024.102973
61.    Hochvaldova L, Posselt G, Wessler S, Kvítek L, Panáček A. Implications of silver nanoparticles for H. pylori infection: modulation of CagA function and signaling. Front Cell Infect Microbiol. 2024;14:1419568. doi:10.3389/fcimb.2024.1419568
62.    Hites M, Massonnaud CR, Lapique EL, et al. Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled  trial. J Infect. 2024;88(3):106120. doi:10.1016/j.jinf.2024.106120
63.    Hart C, Klamroth R, Sachs UJ, et al. Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A. J Thromb Haemost. 2024;22(10):2692-2701. doi:10.1016/j.jtha.2024.06.010
64.    Gurnari C, Robin M, Adès L, et al. Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT. Blood. Published online February 19, 2025:blood.2024025131. doi:10.1182/blood.2024025131
65.    Grimm MO, Schostak M, Grün CB, et al. Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2024;10(6):755-764. doi:10.1001/jamaoncol.2024.0938
66.    Giulini L, Kemeter M, Farmaki F, et al. Impact of anastomotic leak vs pneumonia on failure to rescue after transthoracic esophagectomy for cancer. J Gastrointest Surg. 2025;29(3):101936. doi:10.1016/j.gassur.2024.101936
67.    Giordano C, Kendler J, Sexl M, et al. Anti-Cancer Potential of a new Derivative of Caffeic Acid Phenethyl Ester targeting the Centrosome. Redox Biol. 2025;81:103582. doi:10.1016/j.redox.2025.103582
68.    Garcha HK, Olaoye OO, Sedighi A, et al. Monoselective Histone Deacetylase 6 PROTAC Degrader Shows In Vivo Tractability. J Med Chem. Published online March 10, 2025. doi:10.1021/acs.jmedchem.4c02021
69.    Fux AC, Casonato Melo C, Schlahsa L, et al. Generation of Endotoxin-Specific Monoclonal Antibodies by Phage and Yeast Display for Capturing Endotoxin. Int J Mol Sci. 2024;25(4). doi:10.3390/ijms25042297
70.    Fuchs M, Jacob AS, Kaul H, et al. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. Leukemia. 2024;38(1):160-167. doi:10.1038/s41375-023-02064-y
71.    Fortelny N, Farlik M, Fife V, et al. JAK-STAT signaling maintains homeostasis in T cells and macrophages. Nat Immunol. 2024;25(5):847-859. doi:10.1038/s41590-024-01804-1
72.    Ferdinandus J, Müller H, Damaschin C, et al. Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized  international GHSG HD18 trial. Ann Oncol. 2024;35(3):276-284. doi:10.1016/j.annonc.2023.11.014
73.    Elmer DP, Stockmaier G, Grund-Gröschke S, et al. Cooperative Hedgehog/GLI and JAK/STAT signaling drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin  cancer. Cell Commun Signal. 2025;23(1):91. doi:10.1186/s12964-025-02101-6
74.    El Kababji S, Mitsakakis N, Jonker E, et al. Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study. J Med Internet Res. 2025;27:e66821. doi:10.2196/66821
75.    Eisazadeh R, Mirshahvalad SA, Schwieghofer-Zwink G, et al. Pre-treatment (68) Ga-PSMA-11 PET/CT Prognostic Value in Predicting Response to (177)Lu-PSMA-I&T Therapy and Patient Survival. Mol Imaging Biol. 2024;26(2):360-369. doi:10.1007/s11307-024-01900-6
76.    Dugo M, Huang CS, Egle D, et al. The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2024;30(21):4900-4909. doi:10.1158/1078-0432.CCR-24-0149
77.    Du M, Xin J, Zheng R, et al. CYP2A6 Activity and Cigarette Consumption Interact in Smoking-Related Lung Cancer Susceptibility. Cancer Res. 2024;84(4):616-625. doi:10.1158/0008-5472.CAN-23-0900
78.    Dorff T, Horvath LG, Autio K, et al. A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024;30(8):1488-1500. doi:10.1158/1078-0432.CCR-23-2978
79.    Dorfer S, Ablinger M, Wimmer M, et al. Repurposing diacerein for the treatment of chronic wounds in recessive-dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase-9  expression. J Dermatol. 2025;52(3):423-431. doi:10.1111/1346-8138.17621
80.    Demkes E, Cervera-Barea A, Ebner-Peking P, et al. Human Cardiac Microtissues Display Improved Engraftment and Survival in a Porcine Model of Myocardial Infarction. J Cardiovasc Transl Res. Published online March 13, 2025. doi:10.1007/s12265-025-10596-0
81.    DeBerg HA, Fahning ML, Varkhande SR, et al. T cells promote distinct transcriptional programs of cutaneous inflammatory disease in keratinocytes and dermal fibroblasts. Published online December 22, 2024. doi:10.1101/2024.07.31.606077
82.    de Castro T, Welland S, Jochheim L, et al. Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort. Hepatol Commun. 2024;8(11). doi:10.1097/HC9.0000000000000562
83.    Cohen JN, Gouirand V, Macon CE, et al. Regulatory T cells in skin mediate immune privilege of the hair follicle stem cell niche. Sci Immunol. 2024;9(91):eadh0152. doi:10.1126/sciimmunol.adh0152
84.    Chammartin F, Mocroft A, Egle A, et al. Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human  Immunodeficiency Virus. Clin Infect Dis. 2024;78(4):995-1004. doi:10.1093/cid/ciad671
85.    Canadas-Ortega M, Mühlbacher I, Posselt G, et al. HtrA-Dependent E-Cadherin Shedding Impairs the Epithelial Barrier Function in Primary Gastric Epithelial Cells and Gastric Organoids. Int J Mol Sci. 2024;25(13). doi:10.3390/ijms25137083
86.    Burgmann CH, Sachs UJ, Trautmann-Grill K, et al. Comorbidity and adverse events in acquired hemophilia A: data from the GTH-AHA-EMI study. Res Pract Thromb Haemost. 2024;8(7):102565. doi:10.1016/j.rpth.2024.102565
87.    Brown JR, Seymour JF, Jurczak W, et al. Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. N Engl J Med. 2025;392(8):748-762. doi:10.1056/NEJMoa2409804
88.    Borchmann P, Ferdinandus J, Schneider G, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre,  parallel, open-label, phase 3 trial. Lancet. 2024;404(10450):341-352. doi:10.1016/S0140-6736(24)01315-1
89.    Bekric D, Kiesslich T, Ocker M, et al. The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract  cancer cells. PLoS One. 2024;19(4):e0302050. doi:10.1371/journal.pone.0302050
90.    Bauer R, Dang HH, Neureiter D, et al. NLRP3 promotes allergic responses to birch pollen extract in a model of intranasal sensitization. Front Immunol. 2024;15:1393819. doi:10.3389/fimmu.2024.1393819
91.    Andrew TW, Koepke LS, Wang Y, et al. Author Correction: Sexually dimorphic estrogen sensing in skeletal stem cells controls skeletal regeneration. Nat Commun. 2024;15(1):8030. doi:10.1038/s41467-024-51829-1
92.    Amrutha MC, Wessler S, Ponnuraj K. Biophysical characterization and in silico analysis of natural and synthetic compounds targeting Listeria monocytogenes HtrA protease. Mol Divers. Published online November 28, 2024. doi:10.1007/s11030-024-11050-0
93.    Ablinger C, Neureiter D, Mähr T, et al. The Cdk inhibitor dinaciclib as a promising anti-tumorigenic agent in biliary tract cancer. Cancer Biol Ther. 2024;25(1):2439057. doi:10.1080/15384047.2024.2439057​